caa a22 4500 469074191 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF01741755 doi (NATIONALLICENCE)springer-10.1007/BF01741755 Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer [Elektronische Daten] [Darcy Spicer, Ann Kelley, Robin Herman, Grace Dean, Lucy Stevenson, Malcolm Mitchell] Summary: We undertook a preliminary study to examine the response rate of recombinant interleukin-2 (rIL-2) in patients with advanced measurable breast cancer, in a phase II clinical trial. The regimen we utilized was designed to allow outpatient administration. A treatment cycle consisted of low-dose cyclophosphamide (350 mg/m2) given on day -3 followed by the bolus administration of rIL-2 (3.6 × 106 Cetus units/m2) on days 1-5, and 8-12. Toxicity was significant but acceptable. One partial remission was seen in 13 evaluable patients. In 2 additional patients clear evidence of an antitumor response was observed. The study was terminated prematurely owing to a shortage of rIL-2. Additional evaluation of rIL-2 in breast cancer appears warranted. Springer-Verlag, 1992 Interleukin-2 nationallicence Cytokines nationallicence Breast cancer nationallicence Immunotherapy nationallicence Spicer Darcy Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut Kelley Ann Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut Herman Robin Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut Dean Grace Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut Stevenson Lucy Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut Mitchell Malcolm Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 34/6(1992-11-01), 424-426 0340-7004 34:6<424 1992 34 262 https://doi.org/10.1007/BF01741755 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741755 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Spicer Darcy Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Kelley Ann Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Herman Robin Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Dean Grace Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Stevenson Lucy Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Mitchell Malcolm Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/6(1992-11-01), 424-426 0340-7004 34:6<424 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer